Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OnKure Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OnKure Therapeutics's regulatory disclosures and financial reporting.
OnKure Therapeutics director Michael G. Grey received a grant of 22,350 stock options to purchase Class A common stock at an exercise price of $4.14 per share. All options vest on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, subject to continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 options directly.
OnKure Therapeutics, Inc. reported that director R Michael Carruthers received a grant of stock options covering 22,350 shares of Class A common stock on August 7, 2026. The options have an exercise price of $4.14 per share, expire on August 6, 2036, and will vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to continued service.
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of stock options for 150,000 shares of Class A Common Stock on August 7, 2026, with an exercise price of $4.14 per share and vesting in equal monthly installments over 48 months starting September 7, 2026, subject to continued service.
The company also implemented a one-time stock option repricing effective August 7, 2026 for options with exercise prices of at least $10.00 per share. Several of the CEO’s existing options with exercise prices of $21.20, $13.99, and $18.20 per share were reported as dispositions to the issuer and regrants at an amended exercise price of $4.14 per share. Footnotes state that there was no change to the vesting schedules, expiration dates, or number of shares underlying the repriced options, and that a "Retention Period" runs from August 7, 2026 until the earlier of February 7, 2028 or a Change in Control, during which early exercise of repriced options requires payment of the original higher exercise price.
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received a new option grant for 50,000 shares of Class A common stock at an exercise price of $4.14 per share, expiring in 2036. He also participated in a one-time option repricing, with previously granted options for 5,781, 5,322, and 130,611 shares surrendered to the issuer and concurrently regranted with a reduced exercise price of $4.14 per share, while maintaining the same vesting schedules, expiration dates, and number of underlying shares. Footnotes state that repriced options require paying the original higher exercise price if exercised before the end of a defined Retention Period.
OnKure Therapeutics, Inc. reported equity compensation changes for Chief Scientific Officer Dylan Hartley involving stock options on Class A Common Stock. Hartley received a new grant of 50,000 employee stock options with an exercise price of $4.14 per share, expiring on August 6, 2036; 1/48 of these options vest on September 7, 2026 and monthly thereafter, conditioned on continued service. In addition, a one-time Option Repricing effective August 7, 2026 applied to options with exercise prices at or above $10.00 held by continuing employees and certain service providers. In connection with this repricing, 137,603 options with a prior exercise price of $18.20 were reported as disposed to the issuer and a corresponding 137,603 options were granted back to Hartley with a revised exercise price of $4.14 per share, keeping the original vesting schedule (1/4 vested on June 9, 2025 and 1/48 vesting monthly thereafter), expiration date of October 3, 2034, and number of underlying shares unchanged. During a defined Retention Period starting August 7, 2026 and ending on the earlier of February 7, 2028 or a Change in Control, any early exercise of these repriced options requires paying the original higher exercise price rather than the reduced $4.14.
OnKure Therapeutics, Inc. reported multiple stock option adjustments for Chief Medical Officer Samuel Agresta effective August 7, 2026. The company implemented a one-time Option Repricing for employee options with exercise prices at or above $10.00 per share, resetting the exercise price of affected options, including Mr. Agresta’s, to $4.14 per share, the closing price of the Class A Common Stock on the effective date. There was no change to vesting schedules, expiration dates or the number of underlying shares. A Retention Period applies: if a repriced option is exercised before the earlier of February 7, 2028 or a Change in Control, the holder must pay the original, higher exercise price; otherwise the reduced $4.14 exercise price applies.
OnKure Therapeutics, Inc. is the subject of an amended Schedule 13G filed by Prosight Management, LP and related entities, together with W. Lawrence Hawkins, reporting beneficial ownership of the company’s Class A Common Stock. Prosight Management, certain Prosight funds, separate managed accounts, Prosight Partners, LLC, and Hawkins (collectively the reporting persons) may be deemed to beneficially own 978,992 shares of Class A Common Stock, representing 2.4% of the class, based on 40,395,480 shares outstanding as of May 4, 2026. The reported holdings are held with shared voting and dispositive power and no sole power. Individual fund positions include 45,771 shares (0.1%) for Prosight Fund, LP and 219,725 shares (0.5%) for Prosight Plus Fund, LP. The reporting persons include extensive disclaimers of beneficial ownership and state that ownership is 5% or less of the class.
Okur is amending its existing shelf registration to continue an at-the-market program for the offer and sale of up to $100,000,000 of Class A common stock through or to Leerink Partners under a Sales Agreement. The company states it is no longer subject to General Instruction I.B.6 of Form S-3, which had limited the amount it could sell under this registration.
As of August 4, 2026, no shares have been offered or sold under this program. The aggregate market value of Class A common stock held by non-affiliates was $167.3 million as of August 3, 2026, based on 36,368,892 non-affiliate shares at $4.60 per share; this is a baseline figure, not the amount being offered. Leerink Partners may receive up to 3.0% of gross proceeds as sales compensation. Okur is characterized as an “emerging growth company” and “smaller reporting company,” and investors are directed to the referenced risk factor sections before investing.
OnKure Therapeutics reported second-quarter 2026 results and progress on its PI3Kα-focused precision medicine pipeline. Lead candidates OKI-355 for vascular anomalies and OKI-345 for breast cancer are in IND-enabling activities, with Investigational New Drug submissions planned for the first half of 2027.
The company highlighted scientific engagement through a Key Opinion Leader event on PI3Kα pan-mutant inhibition and participation at the ISSVA World Congress. As of June 30, 2026, cash, cash equivalents and marketable securities were $176.4 million, expected to fund operations into 2029.
For the quarter, research and development expenses were $12.6 million for both the second quarter of 2026 and 2025, while general and administrative expenses were $4.3 million versus $3.7 million a year earlier. Net loss was $15.3 million, or $0.31 per share, compared with $15.4 million, or $1.14 per share, in the prior-year quarter.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting mutant PI3Kα for vascular anomalies and cancers. For the six months ended June 30, 2026, it reported a net loss of $30.5 million, compared with $31.3 million in the prior-year period.
Research and development expenses were $24.3 million and general and administrative expenses were $8.2 million. Cash, cash equivalents and marketable securities totaled $176.4 million, strengthened by a $150.0 million March 2026 private placement of common stock and pre-funded warrants. Management believes this liquidity funds its current operating plan for at least the next 12 months as it prepares IND submissions for OKI-345 and OKI-355 in the first half of 2027.